New modalities flood the EGFR pipeline

A 20-year evolution of small molecule and antibody designs has defined the drug development story for the cancer target EGFR, but new modality therapies will feature in the target’s next chapter. 

Emerging resistance is where the traditional modalities continue to fall short, and that’s what many new modality therapies are designed to prevent, or at least reduce. ...